Atai Life Sciences Announces $130 Million Public Share Offering

2025-10-17 companies

New York, Friday, 17 October 2025.
Atai Life Sciences is launching a $130 million public share offering to fund its mental health drug development pipeline, including treatments for depression and anxiety, with Jefferies LLC as the lead bookrunner.

Details of the Public Offering

Atai Life Sciences N.V. (NASDAQ: ATAI) has announced a registered underwritten public offering of 23,725,000 common shares priced at $5.48 each. Additionally, the company has granted underwriters a 30-day option to purchase up to an additional 3,558,750 shares at the offering price, excluding the underwriting discount. The gross proceeds from this offering are projected to be approximately $130 million [1][2].

Purpose and Impact of the Offering

The company intends to utilize the net proceeds to advance the clinical development of its product candidates and programs, including BPL-003, VLS-01, and EMP-01, which are in Phase 2 clinical trials for mental health disorders. These funds will also support working capital and general corporate purposes, positioning Atai to strengthen its pipeline of innovative treatments in a competitive biopharmaceutical landscape [1][3][4].

Market Context and Strategic Positioning

This offering comes at a strategic time for Atai, following the U.S. FDA’s Breakthrough Therapy designation for its BPL-003 nasal spray, designed for treatment-resistant depression. This designation is expected to expedite the drug’s development and regulatory review processes, with Phase 3 trials anticipated to begin in the second quarter of 2026. Such advancements could significantly enhance Atai’s market position and long-term growth prospects [5][6].

Financial and Market Performance

Despite recent stock volatility, Atai Life Sciences remains committed to expanding its clinical capabilities. The company, with a current market capitalization of $1.28 billion and analyst recommendations suggesting a target price of $11.38, continues to be viewed as undervalued by some market analysts. This public offering is a crucial step towards securing the financial resources necessary for its ambitious clinical objectives [3][7].

Sources

public offering atai Life Sciences